Black Diamond Therapeutics, Inc. - Common Stock (BDTX)

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Equity / Common Stock
Shares outstanding
56,078,244
Total 13F shares
22,835,597
Share change
+929,044
Total reported value
$959,367,654
Price per share
$42.16
Number of holders
79
Value change
+$39,864,306
Number of buys
50
Number of sells
16

Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2020

As of 30 Jun 2020, Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by 79 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 22,835,597 shares. The largest 10 holders included NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., BOXER CAPITAL, LLC, Artal Group S.A., FMR LLC, Bellevue Group AG, WELLINGTON MANAGEMENT GROUP LLP, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, and BlackRock Inc.. This page lists 79 institutional shareholders reporting positions in this security for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.